• SHARE

Daiichi Sankyo Co.’s home-grown COVID-19 vaccine, a cutting-edge mRNA shot that’s on the cusp of its final clinical trials, could be used mainly as a booster starting next year for people who have already been immunized, the drugmaker said.

While inoculations from companies including Pfizer Inc.-BioNTech SE, Moderna Inc. and AstraZeneca Plc. are being rolled out across the globe, many others are still in development. Manufacturers including Daiichi are targeting local markets that don’t have an ample vaccine supply or are anticipating future needs, including booster shots.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)